New Anticancer Drugs: Reliably Assessing "Value" While Addressing High Prices.

Countries face challenges in paying for new drugs. High prices are driven in part by exploding drug development costs, which, in turn, are driven by essential but excessive regulation. Burdensome regulation also delays drug development, and this can translate into thousands of life-years lost. We ne...

Descripción completa

Detalles Bibliográficos

Publicado en:	Current Oncology Vol. 31; no. 5; pp. 2453 - 2481
Autores principales:	Stewart, David J., Bradford, John-Peter, Sehdev, Sandeep, Ramsay, Tim, Navani, Vishal, Rawson, Nigel S. B., Jiang, Di Maria, Gotfrit, Joanna, Wheatley-Price, Paul, Liu, Geoffrey, Kaplan, Alan, Spadafora, Silvana, Goodman, Shaun G., Auer, Rebecca A. C., Batist, Gerald
Formato:	Journal Article
Publicado:	MDPI May2024
Acceso en línea:	Ver este registro en EBSCOhost